MedPal AI approved to buy Eli Lilly drugs – direct access to Mounjaro
MedPal AI has been approved as an authorised purchaser of Eli Lilly pharmaceuticals in the UK. In plain English, the company can now buy and dispense Lilly’s medicines directly, including Mounjaro (tirzepatide) – the UK’s leading GLP-1 weight loss and type 2 diabetes treatment.
For a digital health player that already supplies Wegovy and runs a robotic dispensing hub, this is a meaningful step. It puts MedPal AI closer to the most in-demand product in the category and strengthens the proposition of MedPal.clinic’s clinically supervised weight management pathways.
Why this supply agreement matters for MedPal AI investors
Two points jump out. First, Mounjaro dominates the UK GLP-1 market with roughly 79% share, according to the company. Second, research cited in the RNS suggests around ten times more people in the UK buy Mounjaro privately than receive it through the NHS. That tilts the opportunity squarely towards private prescribing, which is exactly where MedPal.clinic operates.
Being an authorised purchaser is about supply chain control. It can improve reliability of stock and, potentially, procurement economics. Combined with existing Wegovy supply (about 20% market share), MedPal AI can now offer patients their preferred GLP-1 option via a single digital pathway, supported by AI triage and prescriber consultation.
GLP-1 refers to a class of drugs (GLP-1 receptor agonists) that help regulate blood sugar and appetite. They’ve become a major force in both diabetes care and weight management. Access to the leading brand should enhance MedPal AI’s ability to attract and retain patients on its platform.
The UK GLP-1 boom in numbers
MedPal AI’s RNS sets out a sizeable market backdrop, both at home and globally. Here are the key figures:
| Mounjaro UK GLP-1 market share | Approximately 79% |
| Wegovy UK GLP-1 market share | 20% |
| Private purchasers vs NHS for Mounjaro | ~10x more private purchasers |
| UK prescription weight loss meds market | ~£340 million in 2025 to £2 billion by 2033 |
| Eligible for tirzepatide in the UK | ~3.4 million people |
| Adults overweight or obese (England) | ~64% |
| Global GLP-1 weight loss drugs market by 2035 | ~£120 billion |
It’s a picture of strong secular demand. The private-pay channel looks especially attractive in the near term, and direct supply access positions MedPal AI to serve that demand more effectively through MedPal.clinic.
Operational readiness: robotic dispensing in Swaffham
Execution matters in pharmacy. MedPal AI dispenses from its distribution centre in Swaffham, Norfolk, using robotic dispensing to improve accuracy, speed and scalability. The facility runs 24/7 for NHS and private prescriptions, with AI triage integrated to streamline patient journeys and same-day/next-day delivery capabilities noted.
If demand ramps, this sort of automated infrastructure can be a competitive advantage. It helps control fulfilment times and supports consistent patient experience, both of which are crucial in a category where continuity of supply and adherence affect outcomes.
Strategic fit: a tighter loop between AI triage and treatment
The company’s strategy is to build MedPal.clinic into a leading digital platform for supervised weight management, pairing AI-powered triage with access to innovative therapies. Bringing Mounjaro into the fold tightens that loop. It gives clinicians and patients aligned options within one system, potentially reducing drop-off between consultation and fulfilment.
Beyond the clinic, MedPal AI’s app aggregates data from 100+ wearables and health apps, offering non-clinical, personalised guidance. Partnerships mentioned in the RNS – such as Epassi (11M+ employees with zero-cost access for a limited time) and Independent Gyms – could seed distribution and awareness for the wider wellness ecosystem. That may, over time, feed users into clinical pathways where appropriate.
What’s not disclosed and what to watch next
The RNS is clear on approval status but light on commercial terms. Investors should note the following gaps:
- Pricing and margin impact – not disclosed.
- Volume commitments or supply allocations from Eli Lilly – not disclosed.
- Go-live date for dispensing Mounjaro via MedPal.clinic – not disclosed.
- Any exclusivity or preferred partner status – not disclosed.
- Customer acquisition plans and marketing spend for the weight management service – not disclosed.
Near-term catalysts would include confirmation of launch timing, evidence of consistent stock availability, and early patient onboarding metrics. Given the cited split between private and NHS channels, private prescription throughput will be the metric to watch.
Risks and considerations
The company flags standard forward-looking risks: macro conditions, regulatory processes, staffing, competition, technical issues, third-party consents and approvals, and unexpected events. For this specific development, the big swing factors are:
- Supply reliability – allocations from the manufacturer will determine how quickly MedPal AI can scale dispensing. No details are provided in the RNS.
- Regulatory and clinical compliance – GLP-1 prescribing requires appropriate clinical pathways, which MedPal.clinic says it provides via AI triage and prescriber consultation.
- Execution at scale – maintaining fulfilment speed and accuracy as volumes increase.
- Competitive intensity – other providers already operate in the private GLP-1 market.
CEO comment: tone and intent
Jason Drummond calls the approval an “important milestone”, highlighting the combination of direct supply access with AI triage and robotic dispensing. The message is consistent: secure the leading therapy, plug it into a scalable digital-physical infrastructure, and meet growing private demand.
Bottom line: my take on MedPal AI’s Lilly approval
This looks like a strategically sound upgrade. Direct access to Mounjaro – the category leader with approximately 79% UK GLP-1 share – should make MedPal.clinic more compelling for patients and prescribers. The private-pay market is where the action is today, and the company already has the plumbing in place with a 24/7, robot-enabled dispensing centre.
The opportunity is sizeable, with the UK prescription weight loss medications market forecast to grow from about £340 million in 2025 to £2 billion by 2033, and an estimated 3.4 million people eligible for tirzepatide. But the value capture depends on the practicalities: when dispensing starts, how much supply MedPal AI can secure, the unit economics, and how efficiently it can acquire and retain patients.
On balance, positive. It aligns with the strategy, targets a fast-growing market, and shores up the product mix alongside Wegovy. I’ll be watching for launch timing, proof of stock consistency, and early run-rate indicators from MedPal.clinic. Without commercial detail, it’s hard to model the revenue impact yet – but strategically, this is a meaningful step forward.
